Skip to content
  • Home
  • About
    • Management Team
    • Board of Directors
  • Pipeline
    • ENAC PULMONARY (VX-371/P-1037)
    • tPAD
    • Mucolytic Agents
    • CFTR Corrector Program for CF
    • P-321 Dry Eye Disease
    • Clinical Trials
  • News and Events
  • Partnerships
  • Careers
  • Contact

Parion Sciences

Parion Sciences Dry Eye Program Recognized by National Eye Institute (NEI)

October 2, 2014News & EventPaul Boucher
  • View Entire Article

Post navigation

← Parion Sciences Announces $3 Million Award from Cystic Fibrosis Foundation Therapeutics to Accelerate the Development of Novel CF Treatment Parion Sciences Announces $15.6 Million in Grant Support for Pulmonary Research Program →

Recent Posts

  • Shire and Parion Sciences Enter into a Collaborative License Agreement to Advance P-321 for Ophthalmic Indications
  • Topical ENaC blocker serves as novel approach to tear film
  • Parion Sciences Announces Presentation of Clinical Data with Novel Pulmonary Delivery Device at the 2016 North American Cystic Fibrosis Conference
  • Parion Sciences Announces Initiation of Phase 2 Clinical Trial of P-321 for the Treatment of Dry Eye Disease
  • Parion Sciences Announces the Presentation of Clinical Data on P-321 Ophthalmic Solution for the treatment of Dry Eye Disease at the Association for Research in Vision and Ophthalmology (ARVO 2016)

Recent Comments

    Archives

    • May 2017
    • November 2016
    • October 2016
    • July 2016
    • May 2016
    • January 2016
    • October 2015
    • September 2015
    • June 2015
    • May 2015
    • February 2015
    • November 2014
    • October 2014
    • September 2014
    • June 2014
    • May 2014
    • April 2014
    • November 2013

    Categories

    • News & Event
    • Uncategorized

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    Home | About | Pipeline | News & Events | Partnerships | Careers | Contact

    Copyright © 2017. All Rights Reserved.

    Main menu